Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 31,346 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study participants Clear all

Conditions: Leptomeningeal Metastasis
Interventions: Calibration Phase, Stepped Wedge Intervention Phase; Device
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Chronic Pain, Opioid Use Disorder
Interventions: Mindfulness based smartphone app; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 2
States / cities: Phoenix, Arizona

Conditions: Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer
Interventions: Investigational informed consent for chemotherapy, Usual, standard-of-care informed consent for chemotherapy; Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 21 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 8
States / cities: San Francisco, California • Boston, Massachusetts • Milford, Massachusetts + 4 more

Conditions: Cystic Fibrosis
Interventions: TEZ/IVA, IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 6 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 28
States / cities: Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 25 more

Conditions: Diabetic Retinopathy
Interventions: PER-001 Intravitreal Implant - Low Dose, PER-001 Intravitreal Implant - High Dose, PER-001 Intravitreal Implant - Sham; Drug
Lead sponsor: Perfuse Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetic Gastroparesis, Idiopathic Gastroparesis
Interventions: TAK-906 Maleate, Placebo; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 67
States / cities: Dothan, Alabama • Tucson, Arizona • Chula Vista, California + 54 more

Conditions: Seizures
Interventions: Cannabidiol Oral Solution; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 11
States / cities: San Francisco, California • Miami, Florida • Pensacola, Florida + 8 more

Conditions: Hidradenitis Suppurativa
Interventions: Sonelokimab; Drug
Lead sponsor: MoonLake Immunotherapeutics AG; Industry
Eligibility: 12 Years and older
Enrollment: 835 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 49
States / cities: Birmingham, Alabama • North Little Rock, Arkansas • Los Angeles, California + 40 more

Conditions: Healthy Volunteers
Interventions: LY2605541; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Canakinumab, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 11
States / cities: Anaheim, California • Los Angeles, California • Panama City, Florida + 8 more

Conditions: Hepatocellular Carcinoma
Interventions: Livmoniplimab, Budigalimab, Durvalumab, Atezolizumab, Bevacizumab, Tremelimumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 13
States / cities: Duarte, California • Irvine, California • Orange, California + 9 more

Conditions: Open-Angle Glaucoma
Interventions: Blood Collection Only; Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Depression, Psychosis, Anhedonia
Interventions: Transdermal Estradiol, Micronized Progesterone, Matching Placebo Patch, Raclopride C11; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 45 Years to 55 Years · Female only
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Anemia
Interventions: Epoetin alfa 3 times weekly /once weekly, Epoetin alfa once weekly, Epoetin alfa once every two weeks; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 61
States / cities: Glendale, Arizona • Tempe, Arizona • Chula Vista, California + 58 more

Conditions: HIV Infections
Interventions: Tenofovir DF, Zidovudine, Stavudine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 2 Years to 15 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 6
States / cities: Los Angeles, California • Fort Lauderdale, Florida • Jacksonville, Florida + 2 more

Conditions: Vestibular Disorder, Headache, Traumatic Brain Injury
Interventions: Osteopathic Manipulative Treatment; Other
Lead sponsor: Michigan State University; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Mason, Michigan

Conditions: Masked Hypertension, Hypertension, Chronic Renal Insufficiency
Interventions: Antihypertensive medication intensification, Usual care; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Chronic Spontaneous Urticaria
Interventions: Nucala; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Macular Degeneration
Interventions: Abicipar Pegol, Ranibizumab, Sham Procedure; Drug · Other
Lead sponsor: Allergan; Industry
Eligibility: 50 Years and older
Enrollment: 939 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 71
States / cities: Phoenix, Arizona • Tucson, Arizona • Encino, California + 61 more

Conditions: Renal Impairment
Interventions: AZD9977; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 6
States / cities: Northridge, California • DeLand, Florida • Hialeah, Florida + 3 more

Conditions: Tourniquet Placement, Wound Packing
Interventions: Simulation; Other
Lead sponsor: White Plains Hospital; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Timeline: 2019
U.S. locations: 1
States / cities: White Plains, New York

Conditions: Alcohol Abuse, Alcohol Intervention, Transdermal Alcohol Monitoring, Contingency Management, Deposit Contract
Interventions: Deposit Contract, Transdermal Alcohol Monitoring; Behavioral · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Denton, Texas • San Antonio, Texas

Conditions: Renal Carcinoma, Renal Cell Carcinoma, Urothelial Carcinoma, Chromophobe Renal Cell Carcinoma, Translocation Renal Cell Carcinoma
Interventions: Cytokine Induced Memory-like Natural Killer (CIML NK) Cells, Interleukin-2 (IL-2); Biological · Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Infections, Bacterial
Interventions: Gepotidacin, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years to 64 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Las Vegas, Nevada

Search by objective public record fields.

Wearable-Triggered Digital Safety Net for Real-Time Monitoring & Intervention in Leptomeningeal Metastasis

Mindfulness-Based Ecological Momentary Intervention for Opioid Use Disorder and Chronic Pain

Improving Informed Consent for Palliative Chemotherapy

A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation

A Study of PER-001 in Participants With Diabetic Retinopathy

A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis

Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

A Study of LY2605541 in Healthy Participants and in the Elderly

Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) Patients

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

Collection of Blood Specimens From Patients in AL-3789 Studies for Elevated Intraocular Pressure (IOP)

Examining the Effects of Estradiol on Neural and Molecular Response to Reward

An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease

Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children

The Effect of OMT on Functional Outcomes and Anti-inflammatory Biomarkers in Mild to Moderate Traumatic Brain Injury

Treatment of Masked Hypertension

Mepolizumab for the Treatment of Chronic Spontaneous Urticaria

A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

Study to Assess the Pharmacokinetics and Safety of AZD9977 in Participants With Renal Impairment

Effectiveness of the Adding High Fidelity Simulation to the Bleeding Control Course in Regards to Proper Tourniquet Placement Amongst School Personnel

Contingency Management Using Deposit Contract to Reduce Drinking

Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma

Pharmacokinetics of Gepotidacin Tablets in Adults and Adolescents Subjects